创金合信全球医药生物股票发起(QDII)C(018156)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-30,340,879.12 |
6,100,345.59 |
2,468,019.55 |
-1,119,235.47 |
| 利息合计 |
95,286.06 |
80,553.29 |
4,180.70 |
31,469.65 |
| 其中:存款利息收入 |
95,286.06 |
80,553.29 |
4,180.70 |
31,469.65 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-54,101,905.82 |
2,429,763.99 |
1,386,433.96 |
-1,076,376.37 |
| 其中:股票投资收益 |
-55,223,475.60 |
2,377,012.03 |
1,371,706.70 |
-1,139,692.39 |
| 基金投资收益 |
1,078,042.78 |
- |
- |
- |
| 债券投资收益 |
- |
1,299.70 |
- |
61.26 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
43,527.00 |
51,452.26 |
14,727.26 |
63,254.76 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
25,374,306.60 |
3,871,122.26 |
1,026,976.31 |
527.43 |
| 其他收入 |
1,289,189.47 |
1,989,871.28 |
34,439.81 |
8,364.64 |
| 费用 |
3,481,964.54 |
2,320,177.79 |
115,396.04 |
252,870.45 |
| 管理人报酬 |
2,197,658.33 |
1,487,985.73 |
82,018.38 |
184,869.08 |
| 基金托管费 |
366,276.37 |
247,997.72 |
13,669.81 |
30,811.57 |
| 销售服务费 |
694,097.40 |
523,054.70 |
16,976.75 |
30,682.88 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
223,932.44 |
61,139.64 |
2,731.10 |
6,506.92 |
| 利润总额 |
-33,822,843.66 |
3,780,167.80 |
2,352,623.51 |
-1,372,105.92 |